All In Biotech

Drug Trial Radar · NCT00478205

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Jul 11, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,467 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,467

Actual

Start

Jun 2007

Primary completion

Jun 2009

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
Collaborators
Eisai Limited
First posted
May 24, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 45 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer's disease.

Conditions

  • Alzheimer's Disease

Interventions

  • Aricept (donepezil SR 23 mg)Drug

    Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design: 23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation.

  • Aricept (donepezil IR 10 mg)Drug

    Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design: 10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 24 in SIB Total ScoreTime frame: Baseline and Week 24
  2. Overall Change From Baseline in Modified CIBIC+ to Week 24Time frame: Baseline and Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MedTrials, Inc.

    Hickory, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.